Resumen de: US2020023049A1

The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

Resumen de: US2020023050A1

An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. pneumoniae, Group B Streptococcus, H. influenzae, S. typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.

Resumen de: US2020024647A1

The present disclosure relates to a PCR detection kit for rapidly identifying Salmonella of specific serotypes. The kit includes primers for detecting tcpS gene, the primers for detecting the tcpS gene including a forward primer having a nucleotide sequence as set forth in SEQ ID NO. 1 and a reverse primer having a nucleotide sequence as set forth in SEQ ID NO. 2. The kit can identify Salmonella of enteritidis, pullorum/gallinarum, and dublin serotypes rapidly and in a high throughput, which can be used as an auxiliary method for the conventional serotyping of Salmonella.

Resumen de: WO2020017947A2

A method for the simultaneous detection of a combination of multiple Gram-positive bacteria and/or Gram-negative bacteria in a sample, the method comprising: providing DNA extracted from the sample; preparing a reaction mixture containing the DNA, one or more pairs of oligonucleotide primers having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 11, SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 16 and SEQ ID NO: 17 and combinations of same, and one or more oligonucleotide probes having a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 and combinations of same; amplifying the DNA included in the reaction mixture, by means real-time polymerase chain reaction; and simultaneously determining the presence or absence of Gram-positive bacteria and/or Gram-negative bacteria in the sample. The method can be used to identify any combination of three species of Gram-positive bacteria (Listeria ssp., Listeria monocytogenes and Staphylococcus aureus) and three species of Gram-negative bacteria (Escherichia coli spp., Escherichia coli O157:H7 and Salmonella spp.).

Resumen de: US2020017904A1

Disclosed are novel genetic arrays for use in the molecular detection of multiple Salmonella serovars, common food-borne and water-borne pathogens. The arrays may be used to simultaneously detect multiple food safety Salmonella serovars. The multiplex-detection methods have improved sensitivity and specificity for the detection of multiple high-impact food-borne pathogens simultaneously. Real-time PCR assaying techniques using such serovars include microarrays.

Resumen de: WO2018096013A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Resumen de: CN110669714A

本发明属于微生物领域，具体涉及一种肠炎沙门菌双基因敲除减毒疫苗候选株CZ14‑1ΔspiCΔnmpC的构建与应用。本发明的肠炎沙门菌减毒疫苗候选株，为将肠炎沙门菌CZ14‑1的spiC基因及nmpC基因敲除后获得。本发明还进一步公开了所述肠炎沙门菌减毒疫苗候选株的制备方法与用途。本发明实现了对肠炎沙门菌减毒菌株的进一步减毒。为研制肠炎沙门菌减毒活疫苗及活载体疫苗奠定基础。

Resumen de: US2020010503A1

Provided herein are methods of producing a heterologous polypeptide and compositions comprising same.

Resumen de: US2020010517A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

Resumen de: WO2020009216A1

The inventors discovered that combined administration, to a subject, of the SseJ protein originating from genus Salmonella with killed bacteria of genus Salmonella yields far better protective effects against Salmonella infection, as compared to when the two are administered individually. As a result, provided is a vaccine that is highly safe and exhibits superior protective ability against salmonellosis.

Resumen de: US2020009240A1

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.

Resumen de: WO2020008475A1

The present invention relates to novel Shigella vaccine formulation and process to prepare said vaccine formulation. More particularly, the present invention relates to inactivated whole cell Shigella vaccine formulation comprising whole cell inactivated Shigella strain selected from Shigella flexneri 2a, Shigella 3a, Shigella 6 and Shigella sonnei, alone or in combination with or without adjuvant and a process to prepare thereof.

Resumen de: US2020013488A1

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

Resumen de: US2020010895A1

A method for identifying a subject having at least an indication or predisposition for developing inflammatory bowel disease or colorectal cancer based upon the presence of Salmonella AvrA protein, nucleic acids and antibodies is provided as is a method for treating Salmonella infection-related colorectal cancer using a Wnt1 agonist.

Resumen de: US2020002769A1

Provided is a non-invasive method for diagnosing colorectal cancer in a subject by detecting enrichment or reduction of certain bacterial species. A kit and device useful for such methods are also provided. In addition, a method for reducing the risk of colon cancer by regulating the pertinent bacterial species in human colon is also provided.

Resumen de: US2020003773A1

The present disclosure provides a substrate. The substrate includes a metallic layer. The substrate further includes a boronic acid component, a nucleic acid component, or both at least partially coating the metallic layer.

Resumen de: EP3586855A1

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity againstEscherichia colistrains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Resumen de: US2019389913A1

A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

Resumen de: NZ707777A

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Resumen de: US2015072338A1

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

Resumen de: US2019382717A1

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Resumen de: US2019381139A1

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

Resumen de: WO2015117711A1

The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Figure 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in Figure 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

Resumen de: WO2018145180A1

The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which therapeutically effective amount of a Immmological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. In other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.

Resumen de: WO2018096007A2

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.